Clinical trial NCT04642924: SGM-101 in Locally Advanced and Recurrent Rectal Cancer
Official title: Multicenter, Open-label, Controlled, Parallel Arms Clinical Study on the Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen (CEA) Monoclonal Antibody, for Locally Advanced or Recurrent Rectal Cancer Patients Undergoing Curative Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Rectal Cancer
Recurrent Rectal Cancer
Lead sponsor: Leiden University Medical Center
Sponsor class: OTHER
Collaborators: name: Erasmus Medical Center
name: Amsterdam UMC, location VUmc
name: Catharina Ziekenhuis Eindhoven
name: Medical Center Haaglanden
name: Surgimab
name: Quest Medical Imaging
name: Centre for Human Drug Research, Netherlands
First posted: 2020-11-24
Enrollment: 203
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospectively inclusion treatment arm. Compared to historical cohort.
Primary purpose: TREATMENT

Brief summary: Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness, which can be difficult to detect with conventional visual and tactile feedback. Hence, this information could aid in intra-operative decision making and therewith foster complete resection margins and less extensive surgery. Subsequently, this may drastically improve patient care by improving oncologic outcome.


Eligibility criteria: Inclusion Criteria:

1. Patients aged over 18 years old;
2. All women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment.
3. Patients should be scheduled and eligible for surgery because of a clinical diagnosis of T3 with a threatened CRM or T4 rectal cancer (locally advanced) or recurrent rectal cancer. (UICC. TNM classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000)
4. Patients should be capable and willing to give signed informed consent before study specific procedures.

Exclusion Criteria:

1. Other malignancies, either currently or in the past five years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma.
2. Patients with a history of, or recently diagnosed with, peritoneal metastases (even those diagnosed during surgery)
3. Patients with a recent history (within the last 3 years) of other distant metastases (even those diagnosed during surgery)
4. Patient with a history of a clinically significant allergy.
5. Patients pregnant or breastfeeding lack of effective contraception in male or female patients with reproductive potential;
6. Laboratory abnormalities defined as:

   1. Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;
   2. Total bilirubin above 2 times the ULN or;
   3. Serum creatinine above 1.5 times the ULN or;
   4. Platelet count below 100 x 109/L or;
   5. Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);
   6. Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;
7. Any condition that the investigator considers to be potentially jeopardizing the patients' well-being or the study objectives.
8. Previous administration of SGM-101

Primary outcomes:
measure: Resection status
timeFrame: 10 days post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Amsterdam University Medical Center
city: Den Haag
country: Netherlands
facility: Haaglanden Medisch Centrum
city: Eindhoven
country: Netherlands
facility: Catharina Hospital Eindhoven
city: Rotterdam
country: Netherlands
facility: Erasmus Medical Center
Study officials:
References: